1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics and outcomes of randomized patients^{^a}
Characteristic <150-mm Hg Target (n = 37) <180-mm Hg Target (n = 36) P Value
Age (yr) 71.0 ± 12.5 68.7 ± 11.1 .40
Male 26 (70%) 28 (78%) .47
Symptom onset to randomization (hr) 10.5 ± 7.4 9.7 ± 7.0 .65
Medical history 
    Hypertension 26 (70%) 27 (75%) .71
    Previous ICH 4 (11%) 1 (3%) .19
    Antiplatelet/anticoagulation 4 (11%) 4 (11%) .74
    Ischemic stroke 6 (16%) 2 (6%) .17
Clinical characteristics 
    Systolic BP (mm Hg) 182 ± 20 184 ± 25 .66
    Diastolic BP (mm Hg) 94 ± 19 97 ± 23 .53
    Mean arterial pressure (mm Hg) 123 ± 17 126 ± 22 .54
    Glasgow Coma Scale 13.3 ± 2.7 13.9 ± 1.9 .27
    NIHSS score 12.3 ± 7.7 11.5 ± 6.3 .64
Hematoma characteristics 
    Basal ganglia 28 (76%) 27 (75%) .99
    Lobar 9 (24%) 8 (22%) 
    Cerebellum 0 (0%) 1 (3%) 
    Intraparenchymal volume (mL) 24.5 ± 28.9 22.61 ± 21.35 .75
    Intraventricular volume (mL) 2.20 ± 6.26 4.25 ± 8.78 .26
    Total ICH volume (mL) 26.68 ± 31.50 26.86 ± 25.24 .98
Antihypertensive therapy^{^b} 
    Labetalol (No.) (mean dose ± SD in mg) 34 (38 ± 25) 16 (29 ± 25) 
    Hydralazine (No.) (mean dose ± SD in mg) 18 (22 ± 14) 5 (14 ± 8) 
    IV enalapril (No.) (mean dose ± SD in mg) 9 (1.25 ± 0) 3 (1.25 ± 0) 
Outcomes 
    Mortality (No.) (%) 7 (19) 4 (11) .52
    Modified Rankin Scale score (median) (IQR) 3 (1.5–5.5) 4 (2–5) .43
    Hematoma growth >6 mL (No.) (%) 8 (21) 8 (22) .86
Note:—IQR indicates interquartile range.
↵a Data are means unless otherwise specified.
↵b Nineteen patients in the <150-mm Hg group and 2 patients in the <180-mm Hg group received multiple antihypertensives.